Dr. Seng-Ho Jeon holds a PhD in Pharmaceutical Sciences from Yonsei University, an MBA from Aalto University School of Business, a Master’s degree in Pharmaceutical Sciences from Seoul National University, and a Bachelor’s degree in Pharmacy from Seoul National University.

He served as CEO and President of Daewoong Pharmaceutical from 2018 to 2024, where he led the company’s growth and global expansion. He also held concurrent leadership roles, including CEO of Affycell Therapeutics (2020 to April 2024) and CEO of Daewoong Investment (2023 to April 2024). In addition, he has been serving as an advisor and board member at the Future Medicine Research Foundation since 2021.

Jung In Kim joined Kolon TissueGene in 2022 as the Chief Financial Officer. Before she joined Kolon TissueGene, she served as a director of the Management and Finance division in Kolon Corporation. She received her Bachelor of Arts in Mathematics at Kookmin University in Korea and acquired her CPA license from Korea Institute of Certified Public Accountant.

Gun-Young Park joined Kolon TissueGene in 2022 and currently serves as Chief Operating Officer. Prior to joining Kolon TissueGene, he worked in the Secretariat of the One&Only Committee at Kolon Corporation since 2018. From 2007 to 2018, he served in the Strategic Planning Team at Kolon Life Science. He received his Bachelor of Arts in Economics and Business from Ajou University in Korea in 2007.

Thierry Uh has served as Chief Business Officer of Kolon TissueGene since 2026. He previously served as Chief Commercial Officer of Kolon TissueGene from 2025 to 2026. Prior to joining Kolon TissueGene, he served as President and CEO of Daewoong Innovation Holdings, where he led Daewoong’s global open-collaboration initiatives. His previous roles include serving as a Partner at FreeMind Investment and as a Board Director and Head of Business Development at AffyXell Therapeutics. He earned his degree in Veterinary Medicine from Chungnam National University and a master’s degree in Veterinary Medicine from Seoul National University.

Andy Weymann has served as Fractional Chief Medical Officer at Kolon TissueGene since 2026. Previously, he served as Chief Medical Officer at Smith+Nephew from 2012 to 2020. He received his medical degree from the University of Zurich and earned an MBA from the Graduate School of Business at the University of Rochester. He has also completed executive education programs at Harvard Business School, including the Board Program Certification.